Agile Therapeutics Inc (STU:0AL)
€ 9.83 0 (0%) Market Cap: 7.41 Mil Enterprise Value: 4.63 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 19/100

Q1 2020 Agile Therapeutics Inc Earnings Call Transcript

May 05, 2020 / 08:30PM GMT
Release Date Price: €5040 (-0.79%)
Operator

Greetings, and welcome to the Agile Therapeutics First Quarter 2020 Financial Results Conference Call. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Matt Riley, Investor Relations for the company. Please go ahead, sir.

Matthew Riley
Agile Therapeutics, Inc. - Product Manager

Hello, everyone, and welcome to today's conference call to discuss our first quarter financial results for 2020.

Before we start, let me remind you that today's call will include forward-looking statements based on our current expectations, including statements concerning our outlook for the fourth quarter and full year 2020, management's expectations for our future financial and operational performance, our business strategy and commercialization time line, our assessment of the size and value of the combined hormonal contraceptive market and the potential market share for Twirla, among other statements regarding our plans, prospects and expectations. Such statements represent our judgment as of today, are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot